Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 28:4:240.
doi: 10.1186/s40064-015-1013-8. eCollection 2015.

Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study

Affiliations

Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study

Satoshi Ikeda et al. Springerplus. .

Abstract

The aims of this study were to retrospectively review Japanese consecutive cases of polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM), focusing on interstital lung disease (ILD) and malignancy, and to document any differences in the incidence, clinical features, and impact on prognosis among patients with PM, DM, and CADM. We retrospectively reviewed 62 consecutive patients diagnosed with PM, DM, and CADM according to Bohan and Peter's criteria (PM/DM) and Sontheimer's criteria and Gerami's criteria (CADM), focusing on ILD and malignancy. ILD occurrence rates were 48 % (11/23) in patients with PM, 46 % (11/24) in DM, and 100 % (15/15) in CADM. Malignancy occurred during diagnosis or the observation period in 14 patients; 86 % were without ILD, and 64 % were DM without ILD. Multivariate logistic regression analysis showed that the risk of newly diagnosed malignancy was significantly lower in patients with ILD [odds ratio, 0.0688; 95 % confidence interval (CI), 0.00127-0.372; p = 0.00190] and significantly higher in patients with DM (odds ratio, 5.21; 95 % CI, 1.17-23.1; p = 0.0299) than in other patients. Patients with malignancies had shorter survival than those without malignancies; no clinically meaningful difference in survival was observed among the different myositis types and for presence of ILD. In CADM-ILD, 80 % fatal cases died from refractory ILD ≤90 days from the first visit; neither death nor recurrence occurred subsequently. In conclusion, a positive association between DM and malignancy and a negative association between ILD and malignancy were noted. In the present study, malignancy was a predictor of poor long-term prognosis, but ILD were not. ILD associated with CADM contributed greatly to poor short-term prognosis, but neither death nor recurrence occurred subsequently.

Keywords: Clinically amyopathic dermatomyositis; Dermatomyositis; Interstitial lung disease; Malignancy; Polymyositis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Survival curves for the whole population. Comparison of the survival curves with and without malignancy (a), with and without interstitial lung disease (ILD) (b), by the types of myositis (c), by the types of myositis, and by presence or absence of ILD (d)
Fig. 2
Fig. 2
Survival curves for the patients with dermatomyositis. Comparative investigation of the survival curves with and without malignancy (a) and with and without interstitial lung disease (b)

Similar articles

Cited by

References

    1. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22:1300–1303. - PubMed
    1. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumor immunity. Nat Rev Cancer. 2004;4:36–44. doi: 10.1038/nrc1255. - DOI - PubMed
    1. Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol. 2009;36:2704–2710. doi: 10.3899/jrheum.090549. - DOI - PMC - PubMed
    1. Azuma K, Yamada H, Ohkubo M, Yamasaki Y, Yamasaki M, Mizushima M, Ozaki S. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol. 2011;21:178–183. doi: 10.3109/s10165-010-0362-y. - DOI - PubMed
    1. Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med. 1976;84:68–76. doi: 10.7326/0003-4819-84-1-68. - DOI - PubMed

LinkOut - more resources